JP2018517415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517415A5 JP2018517415A5 JP2017564059A JP2017564059A JP2018517415A5 JP 2018517415 A5 JP2018517415 A5 JP 2018517415A5 JP 2017564059 A JP2017564059 A JP 2017564059A JP 2017564059 A JP2017564059 A JP 2017564059A JP 2018517415 A5 JP2018517415 A5 JP 2018517415A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- cell
- cells
- receptor
- cell line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021036808A JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2023025723A JP7836780B2 (ja) | 2015-06-10 | 2023-02-22 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2025048124A JP2025089426A (ja) | 2015-06-10 | 2025-03-24 | がんを処置するための改変ｎｋ－９２細胞 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173701P | 2015-06-10 | 2015-06-10 | |
| US62/173,701 | 2015-06-10 | ||
| US201662337044P | 2016-05-16 | 2016-05-16 | |
| US62/337,044 | 2016-05-16 | ||
| PCT/US2016/036991 WO2016201304A1 (en) | 2015-06-10 | 2016-06-10 | Modified nk-92 cells for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021036808A Division JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018517415A JP2018517415A (ja) | 2018-07-05 |
| JP2018517415A5 true JP2018517415A5 (enExample) | 2019-06-27 |
Family
ID=57504144
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564059A Pending JP2018517415A (ja) | 2015-06-10 | 2016-06-10 | がんを処置するための改変ｎｋ−９２細胞 |
| JP2021036808A Active JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2025048124A Pending JP2025089426A (ja) | 2015-06-10 | 2025-03-24 | がんを処置するための改変ｎｋ－９２細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021036808A Active JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2025048124A Pending JP2025089426A (ja) | 2015-06-10 | 2025-03-24 | がんを処置するための改変ｎｋ－９２細胞 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10738279B2 (enExample) |
| EP (3) | EP4272757A3 (enExample) |
| JP (3) | JP2018517415A (enExample) |
| KR (4) | KR20250027585A (enExample) |
| CN (2) | CN107709552B (enExample) |
| AU (1) | AU2016275030B2 (enExample) |
| CA (1) | CA2987290C (enExample) |
| ES (1) | ES2958720T3 (enExample) |
| IL (2) | IL309167A (enExample) |
| WO (1) | WO2016201304A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112877291A (zh) | 2014-04-10 | 2021-06-01 | 西雅图儿童医院 (Dba西雅图儿童研究所) | 基因修饰的t细胞产品、其制备方法和用途 |
| KR20210014210A (ko) | 2014-05-15 | 2021-02-08 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| EP4272757A3 (en) | 2015-06-10 | 2023-12-27 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| HK1256087A1 (zh) | 2015-08-07 | 2019-09-13 | Seattle Children's Hospital, Dba Seattle Children's Research Institute | 用於实体瘤靶向的双特异性cart细胞 |
| JP7591342B2 (ja) * | 2016-06-08 | 2024-11-28 | プレシゲン，インコーポレイテッド | Ｃｄ３３特異的キメラ抗原受容体 |
| EP3565889B1 (en) * | 2017-01-06 | 2025-03-26 | ImmunityBio, Inc. | Genetically modified nk-92 cells with decreased cd96/tigit expression |
| CA3049652A1 (en) * | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| CA3051866A1 (en) * | 2017-02-01 | 2018-08-09 | Nant Holdings Ip, Llc | Calreticulin-mediated cancer treatment |
| JP2020510646A (ja) * | 2017-02-20 | 2020-04-09 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
| AU2018231193B2 (en) * | 2017-03-08 | 2021-07-22 | Immunitybio, Inc. | Modified NK-92 haNK003 cells for the clinic |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| AU2018245749A1 (en) | 2017-03-27 | 2019-10-03 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| CA3056439A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| EP3601538A4 (en) * | 2017-03-27 | 2021-03-10 | Nantcell, Inc. | ANK AND IL-12 COMPOSITIONS AND METHODS |
| JP6933724B2 (ja) * | 2017-04-05 | 2021-09-08 | コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｂｉｏｓｃｉｅｎｃｅ Ａｎｄ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ | Ｎｋ細胞活性化融合タンパク質、ｎｋ細胞およびそれらを含む医薬組成物 |
| CA3059634A1 (en) * | 2017-04-13 | 2018-10-18 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| TWI676483B (zh) * | 2017-08-06 | 2019-11-11 | 強普生技股份有限公司 | 醫藥套組及其用途 |
| KR20250010043A (ko) | 2017-10-18 | 2025-01-20 | 프레시전 인코포레이티드 | 스페이서를 포함하는 폴리펩타이드 조성물 |
| WO2019084234A1 (en) * | 2017-10-26 | 2019-05-02 | St. Jude Childen's Research Hospital, Inc. | METHODS AND COMPOSITIONS FOR TREATING CD33 + CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS |
| EP3703735A1 (en) * | 2017-11-01 | 2020-09-09 | Nantkwest, Inc. | Nk-92 cells to stimulate anti-cancer vaccine |
| CN111788301A (zh) * | 2017-11-24 | 2020-10-16 | 昂克治疗有限公司 | 靶向肿瘤细胞的经修饰的自然杀伤细胞和自然杀伤细胞系 |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| WO2019127215A1 (en) * | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof |
| CN110028589B (zh) * | 2018-02-07 | 2023-07-21 | 阿思科力(苏州)生物科技有限公司 | 嵌合抗原受体、表达该嵌合抗原受体的nkg2d car-nk细胞及其制备方法和应用 |
| SG11202007156QA (en) | 2018-02-09 | 2020-08-28 | Nat Univ Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| US11813292B2 (en) | 2018-03-12 | 2023-11-14 | Immunity Bio, Inc. | Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity) |
| WO2019182422A1 (ko) * | 2018-03-23 | 2019-09-26 | 주식회사 에스엘바이젠 | 신규 유전자 변형 자연살해 세포주 및 그의 용도 |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| IL321548A (en) | 2018-05-22 | 2025-08-01 | Immunitybio Inc | Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof |
| US12498363B2 (en) | 2018-08-01 | 2025-12-16 | Immunitybio, Inc. | Combined invasion and cytotoxicity assay using chemokine secreting target cells |
| JP7241161B2 (ja) * | 2018-08-01 | 2023-03-16 | イミュニティーバイオ、インコーポレイテッド | 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム |
| US12486514B2 (en) | 2018-08-29 | 2025-12-02 | National University Of Singapore | Method to specifically stimulate survival and expansion of genetically-modified immune cells |
| CN112292448B (zh) * | 2018-10-31 | 2025-01-10 | 南克维斯特公司 | 表达cd19-car的nk细胞消除cd19阳性淋巴系统恶性肿瘤 |
| US11077143B2 (en) * | 2018-10-31 | 2021-08-03 | Nantkwest Inc. | Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells |
| KR102569842B1 (ko) * | 2018-11-06 | 2023-08-23 | 난트퀘스트, 인크. | 키메라 항원 수용체-변형된 nk-92 세포 |
| US12109238B2 (en) | 2018-11-06 | 2024-10-08 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells |
| CA3117936A1 (en) * | 2018-11-26 | 2020-06-04 | Immunitybio, Inc. | Il-2 dependent nk-92 cells with stable fc receptor expression |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| CN119040363A (zh) * | 2019-03-15 | 2024-11-29 | 河谷细胞有限公司 | 重组erIL-15 NK细胞 |
| TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向ＭＡｄＣＡＭ之免疫耐受性 |
| CN114269377A (zh) * | 2019-07-26 | 2022-04-01 | 南克维斯特公司 | 作为用于肿瘤溶解的有效治疗性产品的抗体预加载cd16+nk-92细胞 |
| US12180283B2 (en) | 2019-08-01 | 2024-12-31 | Immunitybio, Inc. | Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells |
| KR20210033436A (ko) * | 2019-09-18 | 2021-03-26 | 주식회사 에스엘바이젠 | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 |
| US20210106619A1 (en) * | 2019-10-10 | 2021-04-15 | Nantkwest, Inc. | NK-92 Bone and Brain targeting |
| WO2021101467A1 (en) * | 2019-11-19 | 2021-05-27 | Acibadem Mehmet Ali̇ Aydinlar Üni̇versi̇tesi̇ | A method for redesign and expansion of nk92 cells for use in immunotherapy |
| CN115190910A (zh) * | 2019-11-20 | 2022-10-14 | 免疫生物公司 | 细胞介导的免疫增强分子到肿瘤微环境中的瞬时递送 |
| WO2021116913A1 (en) * | 2019-12-09 | 2021-06-17 | Nantkwest, Inc. | Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| EP4097219A4 (en) * | 2020-01-28 | 2023-10-11 | ImmunityBio, Inc. | Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors |
| CN115397973A (zh) * | 2020-01-30 | 2022-11-25 | 免疫生物公司 | 表达car的nk细胞消除bcma阳性恶性肿瘤 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| AU2021246671A1 (en) * | 2020-03-28 | 2022-10-13 | Board Of Regents, The University Of Texas System | Cell immunotherapy for the treatment of cancer |
| KR102594083B1 (ko) | 2020-07-07 | 2023-10-25 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| WO2022093863A1 (en) * | 2020-10-26 | 2022-05-05 | Research Institute At Nationwide Children's Hospital | Chimeric antigen receptor (car) nk cells and uses thereof |
| WO2022113056A1 (en) | 2020-11-30 | 2022-06-02 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| WO2024236557A1 (en) | 2023-05-12 | 2024-11-21 | Gilboa Therapeutics LTD | Compositions comprising an fc domain for the treatment of medical conditions |
| WO2025158400A1 (en) * | 2024-01-24 | 2025-07-31 | Yale University | Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69834257T2 (de) | 1997-04-30 | 2007-01-04 | Klingemann, Hans | Natürliche killerzelllinien und verfahren zu ihrer verwendung |
| US8034332B2 (en) | 1997-04-30 | 2011-10-11 | Conkwest, Inc. | Interleukin-secreting natural killer cell lines and methods of use |
| TR200001253T2 (tr) | 1997-11-06 | 2000-11-21 | Roche Diagnostics Gmbh | Tümöre özel antijenler |
| WO2000020460A1 (en) | 1998-10-05 | 2000-04-13 | Ludwig Institute For Cancer Research | Methods for producing human tumor antigen specific antibodies |
| US7098008B2 (en) | 2000-04-25 | 2006-08-29 | Ic&G Do. Ltd. | Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use |
| SE526227C2 (sv) * | 2002-05-15 | 2005-08-02 | North China Pharmaceutical Group | Metod för rening av rekombinant humant serumalbumin |
| EP1513554B9 (en) | 2002-05-30 | 2011-11-09 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| WO2006004518A1 (en) | 2004-07-02 | 2006-01-12 | Avaris Ab | Method for the genetic activation of cells and uses of said cells |
| EP2801583B1 (en) | 2004-07-10 | 2018-04-25 | Fox Chase Cancer Center | Genetically modified human natural killer cell lines |
| DE602008006041D1 (de) * | 2007-01-30 | 2011-05-19 | Forerunner Pharma Res Co Ltd | CHIMÄRER Fc GAMMA REZEPTOR UND VERFAHREN ZUR BESTIMMUNG VON ADCC-AKTIVITÄT UNTER VERWENDUNG DES REZEPTORS |
| EP2161339A1 (en) * | 2008-08-29 | 2010-03-10 | F. Hoffmann-La Roche Ag | ADCC with modified NK92 cells |
| US20130189268A1 (en) | 2010-06-22 | 2013-07-25 | Precision Biologics, Inc. | Colon and pancreas cancer specific antigens and antibodies |
| ES2602743T3 (es) | 2010-09-08 | 2017-02-22 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP6053688B2 (ja) | 2011-10-07 | 2016-12-27 | 国立大学法人三重大学 | キメラ抗原受容体 |
| CA2851795C (en) | 2011-10-20 | 2018-11-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| AU2013312838B2 (en) | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| CN112458057A (zh) | 2012-10-02 | 2021-03-09 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| WO2014099671A1 (en) | 2012-12-20 | 2014-06-26 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| ES3058841T3 (en) * | 2013-03-15 | 2026-03-13 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| BR112015027567B1 (pt) * | 2013-05-03 | 2024-02-20 | Ohio State Innovation Foundation | Polipeptídeo, sequência de ácido nucleico isolada, vetor, método de obtenção de célula, uso de uma célula |
| CN104561069A (zh) * | 2013-10-23 | 2015-04-29 | 深圳先进技术研究院 | 含重组嵌合抗原受体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用 |
| CN120501764A (zh) * | 2013-11-01 | 2025-08-19 | 免疫生物公司 | 杀肿瘤和抗微生物组合物和方法 |
| SG11201603484PA (en) * | 2013-11-21 | 2016-05-30 | Ucl Business Plc | Cell |
| EP4272757A3 (en) | 2015-06-10 | 2023-12-27 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| CN112292448B (zh) * | 2018-10-31 | 2025-01-10 | 南克维斯特公司 | 表达cd19-car的nk细胞消除cd19阳性淋巴系统恶性肿瘤 |
-
2016
- 2016-06-10 EP EP23176181.8A patent/EP4272757A3/en active Pending
- 2016-06-10 IL IL309167A patent/IL309167A/en unknown
- 2016-06-10 CA CA2987290A patent/CA2987290C/en active Active
- 2016-06-10 EP EP16808427.5A patent/EP3307876B1/en active Active
- 2016-06-10 KR KR1020257004508A patent/KR20250027585A/ko active Pending
- 2016-06-10 WO PCT/US2016/036991 patent/WO2016201304A1/en not_active Ceased
- 2016-06-10 US US15/531,109 patent/US10738279B2/en active Active
- 2016-06-10 JP JP2017564059A patent/JP2018517415A/ja active Pending
- 2016-06-10 KR KR1020187000382A patent/KR102526538B1/ko active Active
- 2016-06-10 CN CN201680033667.9A patent/CN107709552B/zh active Active
- 2016-06-10 IL IL255884A patent/IL255884B2/en unknown
- 2016-06-10 AU AU2016275030A patent/AU2016275030B2/en active Active
- 2016-06-10 KR KR1020247001893A patent/KR20240013282A/ko not_active Ceased
- 2016-06-10 EP EP24185893.5A patent/EP4424326A3/en active Pending
- 2016-06-10 ES ES16808427T patent/ES2958720T3/es active Active
- 2016-06-10 KR KR1020237013832A patent/KR102627811B1/ko active Active
- 2016-06-10 CN CN202110790574.3A patent/CN113502270B/zh active Active
-
2020
- 2020-07-27 US US16/940,018 patent/US11788059B2/en active Active
-
2021
- 2021-03-09 JP JP2021036808A patent/JP7275178B2/ja active Active
-
2023
- 2023-09-07 US US18/463,213 patent/US20240002802A1/en active Pending
-
2025
- 2025-03-24 JP JP2025048124A patent/JP2025089426A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517415A5 (enExample) | ||
| Roberts et al. | Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL | |
| JP2024099850A5 (enExample) | ||
| Ochoa et al. | Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells | |
| JP2020509767A5 (enExample) | ||
| JP2022159548A5 (enExample) | ||
| IL278348B1 (en) | Methods and compositions for treating cancer | |
| AU2016216149B2 (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| JP2016520074A5 (enExample) | ||
| JP2020516654A5 (enExample) | ||
| JP2021508255A5 (enExample) | ||
| JP2017513478A5 (enExample) | ||
| MX2011012047A (es) | Inmunoglobulinas humanas anti-cd52. | |
| JP2012254083A5 (enExample) | ||
| JP2017515460A5 (enExample) | ||
| JP2019537433A5 (enExample) | ||
| JP2015535691A5 (enExample) | ||
| JP2015527070A5 (enExample) | ||
| JP2017509342A5 (enExample) | ||
| Atar et al. | Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia | |
| JP2014518615A5 (enExample) | ||
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| RU2016143155A (ru) | Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака | |
| JP2022520871A (ja) | ナチュラルキラー細胞およびキメラ抗原受容体改変された細胞の拡大増殖 | |
| JP2019527204A5 (enExample) |